{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:24:13Z","timestamp":1793384653351,"version":"4.5.0"},"reference-count":108,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1053\/j.semnuclmed.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T01:19:29Z","timestamp":1551489569000},"page":"313-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Radionuclide Therapy of Metastatic Prostate Cancer"],"prefix":"10.1053","volume":"49","author":[{"given":"Clemens","family":"Kratochwil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0001","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0002","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0004","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0006","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0007","unstructured":"Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0008","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0009","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0360-3016(93)90309-J","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MNM.0b013e32825a6adc","article-title":"A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases","volume":"28","author":"Liepe","year":"2007","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0011","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","article-title":"Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00259-017-3673-9","article-title":"A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial","volume":"44","author":"van Dodewaard-de Jong","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0014","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2015.09.005","article-title":"Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: A systematic review","volume":"70","author":"Jong","year":"2016","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0016","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","article-title":"Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial","volume":"16","author":"Serafini","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0017","article-title":"Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: New recommendations and future perspectives","author":"van der Doelen","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0018","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.eururo.2013.10.055","article-title":"Visceral disease in castration-resistant prostate cancer","volume":"65","author":"Pezaro","year":"2014","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0019","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.semnuclmed.2016.04.004","article-title":"Current status of prostate-specific membrane antigen targeting in nuclear medicine: Clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer","volume":"46","author":"Kratochwil","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0020","first-page":"5237","article-title":"In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen","volume":"60","author":"Smith-Jones","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0021","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1021\/jm801055h","article-title":"Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer","volume":"51","author":"Chen","year":"2008","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0022","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00259-013-2527-3","article-title":"Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer","volume":"41","author":"Lesche","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"10.1053\/j.semnuclmed.2019.02.003_bib0023","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.2967\/jnumed.116.186775","article-title":"Glu-ureido-based inhibitors of prostate-specific membrane antigen: Lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers","volume":"58","author":"Kopka","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0024","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1021\/jm800765e","article-title":"Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: Structural characterization","volume":"51","author":"Barinka","year":"2008","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0025","doi-asserted-by":"crossref","first-page":"12711","DOI":"10.1021\/ja104591m","article-title":"A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules","volume":"132","author":"Zhang","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0026","article-title":"First-in-human phase I study of CTT1057, a novel 18F labeled imaging agent with phosphoramidate core targeting prostate specific membrane antigen in prostate cancer","author":"Behr","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2191-219X-2-23","article-title":"A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer","volume":"2","author":"Sch\u00e4fer","year":"2012","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0028","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Bene\u0161ov\u00e1","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0029","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0030","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.18632\/oncotarget.14229","article-title":"Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging","volume":"8","author":"Frigerio","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","article-title":"A Novel \u00b9\u00b9\u00b9In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate cancer","volume":"56","author":"Chatalic","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0032","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14712598.2016.1185412","article-title":"Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle","volume":"16","author":"Dekempeneer","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0033","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0034","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00259-014-2830-7","article-title":"\u2078\u2079Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer","volume":"41","author":"Pandit-Taskar","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0035","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","article-title":"First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake","volume":"57","author":"Pandit-Taskar","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0036","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","article-title":"Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody","volume":"56","author":"Schwartz","year":"2011","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0037","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","article-title":"Single low-dose injection of evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0038","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: Modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0039","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","article-title":"Albumin-binding PSMA ligands: Optimization of the tissue distribution profile","volume":"15","author":"Bene\u0161ov\u00e1","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0040","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","article-title":"Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: Preclinical dosimetry and endoradiotherapy studies","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0041","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.2967\/jnumed.116.188722","article-title":"Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer","volume":"58","author":"Kelly","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0042","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00259-018-4004-5","article-title":"Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors","volume":"45","author":"Kelly","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0043","article-title":"Albumin-binding PSMA ligands: Implications for expanding the therapeutic window","author":"Kelly","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0044","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.7150\/thno.18719","article-title":"177Lu-labeled phosphoramidate-based PSMA inhibitors: The effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice","volume":"7","author":"Choy","year":"2017","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0045","first-page":"279","article-title":"Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: An investigation based on pharmacokinetic modeling","volume":"25","author":"Kletting","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162303","article-title":"Investigating the effect of ligand amount and injected therapeutic activity: A simulation study for 177Lu-labeled PSMA-targeting peptides","volume":"11","author":"Kletting","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0047","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators","volume":"71","author":"Wei","year":"2017","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0048","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2017.02.001","article-title":"Prostate cancer heterogeneity: Discovering novel molecular targets for therapy","volume":"54","author":"Ciccarese","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0049","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0050","article-title":"Dosimetry estimate and initial clinical experience with 90Y-PSMA-617","author":"Rathke","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0051","first-page":"40","article-title":"Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer","volume":"7","author":"Cui","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0052","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1021\/jm401921j","article-title":"\u2076\u2074Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer","volume":"57","author":"Banerjee","year":"2014","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0053","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose deposits from 90Y, 177Lu, 111In, and 161 Tb in micrometastases of various sizes: Implications for Radiopharmaceutical Therapy","volume":"57","author":"Hindi\u00e9","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0054","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.7150\/thno.15132","article-title":"Comparison between three promising \u00df-emitting radionuclides, (67)Cu, (47)Sc and (161)Tb, with emphasis on doses delivered to minimal residual disease","volume":"6","author":"Champion","year":"2016","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0055","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0056","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0057","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0058","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: A pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0059","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-018-4220-z","article-title":"Development and dosimetry of 203 Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy?","author":"Dos Santos","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00259-017-3817-y","article-title":"Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617","volume":"45","author":"Kratochwil","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0061","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J Med Chem"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0062","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","article-title":"Radiation dosimetry and first therapy results with a (124)I\/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy","volume":"41","author":"Zechmann","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0063","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-017-3665-9","article-title":"Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0064","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00259-014-2978-1","article-title":"[\u00b9\u2077\u2077Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer","volume":"42","author":"Kratochwil","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for (177)Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0066","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0067","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0068","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","author":"Kabasakal","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0069","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/mirt.08760","article-title":"Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: Stability, bio-distribution and dosimetry","volume":"26","author":"Kabasakal","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0070","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","article-title":"Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu]DKFZ-PSMA-617","volume":"18","author":"Hohberg","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0071","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","article-title":"Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer","volume":"38","author":"Yadav","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0072","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/RLU.0000000000002102","article-title":"Prediction of normal organ absorbed doses for [177Lu]Lu-PSMA-617 using [44Sc]Sc-PSMA-617 pharmacokinetics in patients with metastatic castration resistant prostate carcinoma","volume":"43","author":"Khawar","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0073","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","article-title":"The 68Ga\/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: Correlation of SUVmax values and absorbed dose estimates","volume":"44","author":"Scarpa","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0074","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions","volume":"58","author":"Okamoto","year":"2017","journal-title":"J Nucl Med"},{"issue":"Suppl 3","key":"10.1053\/j.semnuclmed.2019.02.003_bib0075","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0076","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0077","first-page":"63","article-title":"Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases","volume":"35","author":"Bayouth","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0078","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1088\/0031-9155\/41\/10\/012","article-title":"Cancer therapy using bone-seeking isotopes","volume":"41","author":"Lewington","year":"1996","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0079","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00259-015-3150-2","article-title":"Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride","volume":"43","author":"Pacilio","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0080","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s00259-017-3744-y","article-title":"The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer","volume":"44","author":"Murray","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0081","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2967\/jnumed.117.194209","article-title":"Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq","volume":"59","author":"Rathke","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0082","first-page":"634","article-title":"Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?","volume":"46","author":"Vallabhajosula","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0083","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.116.173757","article-title":"Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate Cancer: A multicenter retrospective analysis","volume":"57","author":"Rahbar","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0084","doi-asserted-by":"crossref","first-page":"12477","DOI":"10.18632\/oncotarget.7245","article-title":"Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer","volume":"7","author":"Ahmadzadehfar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0085","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00259-017-3716-2","article-title":"Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617","volume":"44","author":"Ahmadzadehfar","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0086","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0087","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.juro.2016.02.2969","article-title":"Systemic radioligand therapy with Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer","volume":"196","author":"Heck","year":"2016","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0088","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"Lu-Labe led prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0089","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-016-3481-7","article-title":"Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: Safety, efficacy, and quality of life assessment","volume":"44","author":"Yadav","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0091","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0092","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0022-5347(05)68241-9","article-title":"Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo","volume":"162","author":"Burchardt","year":"1999","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0093","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00259-018-4048-6","article-title":"Comparison of [68Ga]Ga-PSMA-11 PET\/CT with [18F]NaF PET\/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy","volume":"45","author":"Uprimny","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0094","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2967\/jnumed.117.200220","article-title":"Intraindividual comparison of 99mTc-methylene diphosphonate and prostate-specific membrane antigen ligand 99mTc-MIP-1427 in patients with osseous metastasized prostate cancer","volume":"59","author":"Rathke","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0095","article-title":"Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pre-therapeutic imaging and \u201cwhole body\u201d tumor dosimetry with treatment outcomes","author":"Violet","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0096","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0097","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00259-016-3447-9","article-title":"(18)F-labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617","volume":"43","author":"Giesel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(18)31442-8","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","author":"Heck","year":"2018","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0099","doi-asserted-by":"crossref","first-page":"103108","DOI":"10.18632\/oncotarget.21600","article-title":"Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0100","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0101","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright Jr","year":"1996","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0102","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","article-title":"Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: Emerging opportunities and challenges","volume":"51","author":"Bakht","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0103","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-015-0145-8","article-title":"Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy","volume":"5","author":"Meller","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/pros.10199","article-title":"Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models","volume":"54","author":"Denmeade","year":"2003","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0105","article-title":"Rapid modulation of PSMA expression by androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade","author":"Emmett","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0106","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1158\/1078-0432.CCR-12-1175","article-title":"Optimizing cancer treatments to induce an acute immune response: Radiation abscopal effects, PAMPs, and DAMPs","volume":"18","author":"Ludgate","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0107","article-title":"Efficacy of Radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects","author":"Isaacsson Velho","year":"2018","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2019.02.003_bib0108","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/RLU.0000000000002141","article-title":"BRCA2 mutation as a possible cause of poor response to 177Lu-PSMA therapy","volume":"43","author":"Ahmadzadehfar","year":"2018","journal-title":"Clin Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299819300212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299819300212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:35:31Z","timestamp":1757543731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299819300212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":108,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0001299819300212"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.02.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radionuclide Therapy of Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}